ArticleAccounts of chemical research2026
Investigating Structural Heterogeneities of Amyloid Aggregates with Spatially Resolved Infrared Spectroscopy.
Article in Accounts of chemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The aggregation of proteins into fibrillar amyloids is central to the pathology of neurodegenerative disorders. However, the relationship between the structure of amyloid aggregates and disease progression remains incompletely understood, in part because amyloid systems are intrinsically heterogeneous: structurally distinct species coexist at every stage of aggregation, and conventional ensemble-averaged methods cannot always resolve them. This Account describes how infrared spectroscopy can be coupled to different imaging modalities to resolve this heterogeneity at multiple length scales: from single-aggregate level to amyloid species in diseased brain tissues. Our findings demonstrate that (i) early stage tau fibrils exhibit pronounced structural polymorphism without morphological differences, converging to a single dominant conformation upon maturation that unexpectedly includes antiparallel β-sheet structure; (ii) Aβ42 oligomeric heterogeneity propagates through protofibrils into fibrils, where structurally distinct domains coexist along a single fibril, demonstrating that amyloid fibrils can deviate significantly from the canonical parallel cross-β architecture; (iii) Aβ(16-22) fibrils undergo a parallel-to-antiparallel β-sheet transition during maturation through disordered intermediates without morphological change, providing direct evidence of spontaneous structural reorganization in fibrillar species. Beyond single-protein systems, (iv) Aβ42 forms structurally distinct mixed polymorphs when aggregated with sequentially or structurally heterotypic seeds and when coaggregated with α-synuclein, establishing heterotypic interactions as an underappreciated source of aberrant aggregate structures; (v) coaggregation of Aβ with the islet amyloid polypeptide (IAPP) from the monomeric state produces a unique heterotypic polymorph in which both peptides adopt non-native structures, whereas cross-seeding with preformed IAPP fibrils yields predominantly homotypic Aβ aggregates, demonstrating that conformational flexibility at the monomeric stage is required for heterotypic fibril formation. These molecular-level findings are complemented by tissue-scale evidence: (vi) discrete frequency IR imaging reveals that amyloid plaques in AD brain exhibit chemical and structural heterogeneities not reflected in morphology, consistent with in vitro observations; and (vii) optical photothermal infrared (O-PTIR) spectroscopic imaging of vascular amyloid deposits in cerebral amyloid angiopathy (CAA) reveals a disease-stage-dependent increase in antiparallel β-sheet content that correlates specifically with colocalized lipids, recapitulated in vitro by coaggregating Aβ40 with lipid extracts. Collectively, these findings support the view that structural heterogeneity is not merely an artifact of in vitro conditions but a property that can persist in human brain tissues and illustrate how spatially resolved IR spectroscopy can complement cryogenic electron microscopy (cryo-EM) and solid-state NMR in the study of amyloid pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.